<div id="readability-page-1">By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...</div>

BLRX

纽交所高增长板生物技术指数 ETF - First Trust

<p>BioLineRx Ltd.（纳斯达克代码：BLRX）公布了其 2025 财务业绩，显示许可收入为 120 万美元，净运营亏损为 1030 万美元。该公司宣布与 Hemispherian 的合资企业 Tetragon Biosciences 计划在 2026 年 3 月底之前开始对胶质母细胞瘤患者进行筛查</p>

Bioline RX：2025 全年业绩